Timing of immune cell interaction influences glioblastoma immunotherapy, study finds

A joint research team led by professors Sungsu Park of Sungkyunkwan University and Sun‑Ha Paek of Seoul National University College of Medicine has, for the first time, shown that the order in which immune cells encounter glioblastoma cells can decisively affect the outcome of treatment. In controlled laboratory experiments, the investigators varied the timing of immune cell infiltration relative to tumor cell exposure and observed marked differences in tumor regression and survival in mouse models.

The study underscores the complexity of the tumor microenvironment in glioblastoma, a highly aggressive brain cancer that has resisted conventional immunotherapies. By revealing that sequential interactions between immune cells and cancer cells modulate therapeutic efficacy, the findings suggest that timing and scheduling of immunotherapeutic agents could be as critical as their composition. The researchers plan to extend the work to human tissue samples and explore whether adjusting treatment schedules can enhance responses in clinical settings.

If these results translate to patients, they could inform the design of next‑generation immunotherapies and clinical trials that optimize the timing of drug delivery. The work highlights the need for a deeper mechanistic understanding of immune‑tumor dynamics and points toward personalized treatment strategies that consider not only the type of immune cells used but also when they are introduced into the tumor milieu.